NASDAQ:CDIO Cardio Diagnostics (CDIO) Stock Price, News & Analysis $3.61 +0.31 (+9.39%) Closing price 06/27/2025 04:00 PM EasternExtended Trading$3.54 -0.07 (-2.08%) As of 06/27/2025 07:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Cardio Diagnostics Stock (NASDAQ:CDIO) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Cardio Diagnostics alerts:Sign Up Key Stats Today's Range$3.30▼$3.8150-Day Range$3.28▼$15.6052-Week Range$3.22▼$53.10Volume104,539 shsAverage Volume95,878 shsMarket Capitalization$6.28 millionP/E RatioN/ADividend YieldN/APrice Target$60.00Consensus RatingBuy Company OverviewCardio Diagnostics Holdings, Inc. develops and commercializes epigenetics-based clinical tests for cardiovascular disease. It offers Epi+Gen CHD, a three-year symptomatic coronary heart disease (CHD) risk assessment test targeting CHD events, including heart attacks; and PrecisionCHD, an integrated epigenetic-genetic blood test for the early detection of coronary heart disease. Cardio Diagnostics Holdings, Inc. was founded in 2017 and is headquartered in Chicago, Illinois.Read More… Cardio Diagnostics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks65th Percentile Overall ScoreCDIO MarketRank™: Cardio Diagnostics scored higher than 65% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingCardio Diagnostics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageCardio Diagnostics has received no research coverage in the past 90 days.Read more about Cardio Diagnostics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Book Value per Share RatioCardio Diagnostics has a P/B Ratio of 0.51. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Cardio Diagnostics' valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted3.32% of the float of Cardio Diagnostics has been sold short.Short Interest Ratio / Days to CoverCardio Diagnostics has a short interest ratio ("days to cover") of 1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Cardio Diagnostics has recently decreased by 32.83%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCardio Diagnostics does not currently pay a dividend.Dividend GrowthCardio Diagnostics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted3.32% of the float of Cardio Diagnostics has been sold short.Short Interest Ratio / Days to CoverCardio Diagnostics has a short interest ratio ("days to cover") of 1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Cardio Diagnostics has recently decreased by 32.83%, indicating that investor sentiment is improving significantly. News and Social Media2.2 / 5News Sentiment0.94 News SentimentCardio Diagnostics has a news sentiment score of 0.94. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Cardio Diagnostics this week, compared to 0 articles on an average week.MarketBeat FollowsOnly 1 people have added Cardio Diagnostics to their MarketBeat watchlist in the last 30 days. This is a decrease of -75% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Cardio Diagnostics insiders have not sold or bought any company stock.Percentage Held by Insiders22.30% of the stock of Cardio Diagnostics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 8.06% of the stock of Cardio Diagnostics is held by institutions.Read more about Cardio Diagnostics' insider trading history. Receive CDIO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cardio Diagnostics and its competitors with MarketBeat's FREE daily newsletter. Email Address CDIO Stock News HeadlinesCDIO - Cardio Diagnostics Holdings Inc Executives | MorningstarJune 25, 2025 | morningstar.comMCardio Diagnostics secures Japan patent for heart disease biomarkersJune 11, 2025 | investing.comNew Rule Hits in July — The Smart Money Already MovedA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Street and the Big Banks… It gives them the green light to treat a certain tangible asset as equivalent to cold, hard cash. Not stocks. Not real estate. And definitely not the U.S. dollar. We're talking about something they don't want you to notice — because the fewer people who act on this, the better it is for them.June 29 at 2:00 AM | American Alternative (Ad)Cardio Diagnostics Secures Japanese Patent for AI-Driven Cardiovascular Disease Detection TechnologyJune 10, 2025 | businesswire.comCardio Diagnostics Holdings, Inc. (CDIO): A Bull Case TheoryJune 9, 2025 | insidermonkey.comCardio Diagnostics regains Nasdaq compliance following reverse stock splitMay 29, 2025 | msn.comCardio Diagnostics Holdings, Inc. Regains Compliance with Nasdaq Minimum Bid PriceMay 29, 2025 | businesswire.comCardio Diagnostics Regains Nasdaq Compliance by May 2025May 28, 2025 | tipranks.comSee More Headlines CDIO Stock Analysis - Frequently Asked Questions How have CDIO shares performed this year? Cardio Diagnostics' stock was trading at $27.51 at the start of the year. Since then, CDIO stock has decreased by 86.9% and is now trading at $3.61. View the best growth stocks for 2025 here. How were Cardio Diagnostics' earnings last quarter? Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO) released its earnings results on Thursday, May, 15th. The company reported ($0.97) EPS for the quarter, missing analysts' consensus estimates of ($0.06) by $0.91. The firm had revenue of $0 million for the quarter, compared to analyst estimates of $0.05 million. Cardio Diagnostics had a negative net margin of 28,539.39% and a negative trailing twelve-month return on equity of 84.55%. When did Cardio Diagnostics' stock split? Cardio Diagnostics shares reverse split on Tuesday, May 13th 2025.The 1-30 reverse split was announced on Thursday, May 8th 2025. The number of shares owned by shareholders was adjusted after the closing bell on Monday, May 12th 2025. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. Who are Cardio Diagnostics' major shareholders? Cardio Diagnostics' top institutional shareholders include Jane Street Group LLC (4.66%). Insiders that own company stock include Robert Philibert and Meeshanthini Dogan. View institutional ownership trends. How do I buy shares of Cardio Diagnostics? Shares of CDIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Cardio Diagnostics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Cardio Diagnostics investors own include Sangamo Therapeutics (SGMO), NVIDIA (NVDA), MSP Recovery (LIFW), NuCana (NCNA), Recursion Pharmaceuticals (RXRX), SoundHound AI (SOUN) and Caribou Biosciences (CRBU). Company Calendar Last Earnings5/15/2025Today6/29/2025Next Earnings (Estimated)8/12/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:CDIO CIK1870144 Webcardiodiagnosticsinc.com Phone302-281-2147FaxN/AEmployees1Year FoundedN/APrice Target and Rating Average Stock Price Target$60.00 High Stock Price Target$60.00 Low Stock Price Target$60.00 Potential Upside/Downside+1,562.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$8.38 million Net Margins-28,539.39% Pretax Margin-28,539.39% Return on Equity-84.55% Return on Assets-74.63% Debt Debt-to-Equity RatioN/A Current Ratio19.47 Quick Ratio19.47 Sales & Book Value Annual Sales$40 thousand Price / Sales157.04 Cash FlowN/A Price / Cash FlowN/A Book Value$7.10 per share Price / Book0.51Miscellaneous Outstanding Shares1,740,000Free Float1,351,000Market Cap$6.28 million OptionableNot Optionable Beta3.10 These 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (NASDAQ:CDIO) was last updated on 6/29/2025 by MarketBeat.com Staff From Our PartnersElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cardio Diagnostics Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cardio Diagnostics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.